Description

Tirzepatide (LY3298176) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity[1][2][3][4].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Metabolism-sugar/lipid metabolism–C225H348N48O68—iScience. 2024 Feb 27.|bioRxiv. 2023 Dec 7.|J Am Chem Soc. 2023 Dec 13.-[1]Fontanella RA, et al. Tirzepatide prevents neurodegeneration through multiple molecular pathways. J Transl Med. 2024 Jan 29;22(1):114.|[2]Huang L, et al. Tirzepatide inhibits tumor growth in mice with diet-induced obesity. bioRxiv, 2023: 2023.06. 22.546093.|[3]Guo X, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023 Aug 28;14:1146960.–2023788-19-2–4813.45–99.64–CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(C(C)(NC([C@@H](N)CC1=CC=C(O)C=C1)=O)C)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC2=CC=CC=C2)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)CC3=CC=C(O)C=C3)=O)CO)=O)[C@H](CC)C)=O)C)=O)CC(C)C)=O)CC(O)=O)=O)CCCCN)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N4CCC[C@H]4C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N5CCC[C@H]5C(N6CCC[C@H]6C(N7CCC[C@H]7C(N[C@H](C(N)=O)CO)=O)=O)=O)=O)C)=O)=O)CO)=O)CO)=O)=O)=O)=O)C)=O)[C@H](CC)C)=O)CC(C)C)=O)CC8=CNC9=CC=CC=C98)=O)CCC(N)=O)=O)C(C)C)=O)CC=CC=CC=C)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CCC(N)=O)=O)C)=O)C.O=C(O)C(F)(F)F–Cancer; Metabolic Disease; Neurological Disease–DMSO : 50 mg/mL (ultrasonic)–GLP Receptor—-GPCR/G Protein–Peptides